Angiotensin receptors: a new role in cancer?

被引：370

作者：

Deshayes, F ^{[1
]}

Nahmias, C ^{[1
]}

机构：

[1] Inst Cochin, CNRS,UMR 8104, INSERM,U567, Dept Biol Cellulaire, F-75014 Paris, France

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2005年 / 16卷 / 07期

关键词：

D O I：

10.1016/j.tem.2005.07.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

There is increasing evidence that Angiotensin II (AngII), a major regulator of blood pressure and cardiovascular homeostasis, is involved in the regulation of cell proliferation, angiogenesis, inflammation and tissue remodeling, which suggests that this peptide might also play a role in cancer. This review focuses on the expression and function of Angiotensin I-converting enzyme (ACE) and AngII receptors in various aspects of cancer. Recent experimental data suggests that ACE inhibitors and AngII type 1 receptor (AT1R) antagonists have beneficial effects on tumor progression, vascularization and metastasis, and that the AngII type 2 receptor (AT2R) subtype has a potential role in cancer. An overview of the major intracellular signaling pathways associated with AT1R and AT2R activation in cancer cells, as well as in endothelial and inflammatory cells, is presented here.

引用

页码：293 / 299

页数：7

共 69 条

[31] Identification of an interaction between the angiotensin II receptor sub-type AT2 and the ErbB3 receptor, a member of the epidermal growth factor receptor family [J].

Knowle, D ;

Ahmed, S ;

Pulakat, L .

REGULATORY PEPTIDES, 2000, 87 (1-3) :73-82

[32] Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore [J].

Koh, WP ;

Yuan, JM ;

Van Den Berg, D ;

Lee, HP ;

Yu, MC .

CARCINOGENESIS, 2005, 26 (02) :459-464

[33]

Koh WP, 2003, CANCER RES, V63, P573

[34] Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? [J].

Lever, AF ;

Hole, DJ ;

Gillis, CR ;

McCallum, IR ;

McInnes, GT ;

MacKinnon, PL ;

Meredith, PA ;

Murray, LS ;

Reid, JL ;

Robertson, JWK .

LANCET, 1998, 352 (9123) :179-184

[35] Relation between use of anti hypertensive medications and risk of breast carcinoma among women ages 65-79 years [J].

Li, CI ;

Malone, KE ;

Weiss, NS ;

Boudreau, DM ;

Cushing-Haugen, KL ;

Daling, JR .

CANCER, 2003, 98 (07) :1504-1513

[36] Involvement of chymase-mediated angiotensin II generation in blood pressure regulation [J].

Li, M ;

Liu, K ;

Michalicek, J ;

Angus, JA ;

Hunt, JE ;

Dell'Italia, LJ ;

Feneley, MP ;

Graham, RM ;

Husain, A .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (01) :112-120

[37] Angiotensin converting enzyme inhibitors for cancer treatment? [J].

Lindberg, H ;

Nielsen, D ;

Jensen, BV ;

Eriksen, J ;

Skovsgaard, T .

ACTA ONCOLOGICA, 2004, 43 (02) :142-152

[38] Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2:: a 5-year, prospective, randomised, controlled trial [J].

Lindholm, LH ;

Anderson, H ;

Ekbom, T ;

Hansson, L ;

Lanke, J ;

Dahlöf, B ;

de Faire, U ;

Forsén, K ;

Hedner, T ;

Linjer, E ;

Scherstén, B ;

Wester, PO ;

Möller, TR .

LANCET, 2001, 358 (9281) :539-544

[39] Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer [J].

Medeiros, R ;

Vasconcelos, A ;

Costa, S ;

Pinto, DE ;

Lobo, F ;

Morais, A ;

Oliveira, J ;

Lopes, C .

JOURNAL OF PATHOLOGY, 2004, 202 (03) :330-335

[40]

Miyajima A, 2002, CANCER RES, V62, P4176

← 1 2 3 4 5 6 7 →